Cargando…

Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?

BACKGROUND: Opioid dependence treatment traditionally involves methadone clinics, for which dispensing schedules can be cumbersome. Buprenorphine, a partial agonist of the mu receptor and antagonist of the kappa receptor, is a potential outpatient alternative to methadone. Funded by a grant from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sittambalam, Charmian D., Vij, Radhika, Ferguson, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992357/
https://www.ncbi.nlm.nih.gov/pubmed/24765257
http://dx.doi.org/10.3402/jchimp.v4.22902
_version_ 1782312568291852288
author Sittambalam, Charmian D.
Vij, Radhika
Ferguson, Robert P.
author_facet Sittambalam, Charmian D.
Vij, Radhika
Ferguson, Robert P.
author_sort Sittambalam, Charmian D.
collection PubMed
description BACKGROUND: Opioid dependence treatment traditionally involves methadone clinics, for which dispensing schedules can be cumbersome. Buprenorphine, a partial agonist of the mu receptor and antagonist of the kappa receptor, is a potential outpatient alternative to methadone. Funded by a grant from the State of Maryland's Community Health Resources Commission (CHRC), the Buprenorphine Outpatient Outcomes Project (BOOP) evaluates the outcome of Suboxone (buprenorphine/naloxone) treatment on abstinence from heroin use, rates of emergency room visits and hospitalizations, legal issues, and quality of life. METHODS: Active heroin users were recruited between June 2007 and June 2010 and induction therapy with Suboxone was instituted during hospitalization. Once discharged, patients were followed as outpatients for maintenance treatment and counseling. Data were collected from electronic medical records, Maryland state legal records, and SF-36(®) Health Surveys regarding several parameters and patients were categorized according to duration of treatment with Suboxone into one of three groups: <1 month, 1–3 months, and >3 months. RESULTS: A total of 220 participants were included in the study. The age range of participants was 18–67 years with most being African American males. Eighty-three (38%) remained in the study for at least 1 month, with 37 of the 83 (45%) remaining in treatment for >3 months. Ten of the 37 (27%) never relapsed after their longest period of abstinence from heroin. During the first year after initiating treatment with Suboxone, hospitalization and emergency room visit rates for all 220 participants decreased by 45 and 23%, respectively, as compared to the year prior to starting treatment. The number of legal charges for drug possession decreased from 70 to 62. Anecdotally, the quality of life seemed to improve in those who were treated with Suboxone for longer periods of time and received regular counseling. CONCLUSION: Overall, Suboxone is an effective treatment method for heroin addiction and is a viable outpatient therapy option. Individualized treatment plans and counseling must be implemented for maximum benefits to be seen. Retention of patients for a long duration of therapy was difficult, but for those who did remain, benefits were seen in overall health, abstinence from heroin use, cognition, and quality of life.
format Online
Article
Text
id pubmed-3992357
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Co-Action Publishing
record_format MEDLINE/PubMed
spelling pubmed-39923572014-04-24 Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction? Sittambalam, Charmian D. Vij, Radhika Ferguson, Robert P. J Community Hosp Intern Med Perspect Research Article BACKGROUND: Opioid dependence treatment traditionally involves methadone clinics, for which dispensing schedules can be cumbersome. Buprenorphine, a partial agonist of the mu receptor and antagonist of the kappa receptor, is a potential outpatient alternative to methadone. Funded by a grant from the State of Maryland's Community Health Resources Commission (CHRC), the Buprenorphine Outpatient Outcomes Project (BOOP) evaluates the outcome of Suboxone (buprenorphine/naloxone) treatment on abstinence from heroin use, rates of emergency room visits and hospitalizations, legal issues, and quality of life. METHODS: Active heroin users were recruited between June 2007 and June 2010 and induction therapy with Suboxone was instituted during hospitalization. Once discharged, patients were followed as outpatients for maintenance treatment and counseling. Data were collected from electronic medical records, Maryland state legal records, and SF-36(®) Health Surveys regarding several parameters and patients were categorized according to duration of treatment with Suboxone into one of three groups: <1 month, 1–3 months, and >3 months. RESULTS: A total of 220 participants were included in the study. The age range of participants was 18–67 years with most being African American males. Eighty-three (38%) remained in the study for at least 1 month, with 37 of the 83 (45%) remaining in treatment for >3 months. Ten of the 37 (27%) never relapsed after their longest period of abstinence from heroin. During the first year after initiating treatment with Suboxone, hospitalization and emergency room visit rates for all 220 participants decreased by 45 and 23%, respectively, as compared to the year prior to starting treatment. The number of legal charges for drug possession decreased from 70 to 62. Anecdotally, the quality of life seemed to improve in those who were treated with Suboxone for longer periods of time and received regular counseling. CONCLUSION: Overall, Suboxone is an effective treatment method for heroin addiction and is a viable outpatient therapy option. Individualized treatment plans and counseling must be implemented for maximum benefits to be seen. Retention of patients for a long duration of therapy was difficult, but for those who did remain, benefits were seen in overall health, abstinence from heroin use, cognition, and quality of life. Co-Action Publishing 2014-04-14 /pmc/articles/PMC3992357/ /pubmed/24765257 http://dx.doi.org/10.3402/jchimp.v4.22902 Text en © 2014 Charmian D. Sittambalam et al. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sittambalam, Charmian D.
Vij, Radhika
Ferguson, Robert P.
Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?
title Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?
title_full Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?
title_fullStr Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?
title_full_unstemmed Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?
title_short Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction?
title_sort buprenorphine outpatient outcomes project: can suboxone be a viable outpatient option for heroin addiction?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992357/
https://www.ncbi.nlm.nih.gov/pubmed/24765257
http://dx.doi.org/10.3402/jchimp.v4.22902
work_keys_str_mv AT sittambalamcharmiand buprenorphineoutpatientoutcomesprojectcansuboxonebeaviableoutpatientoptionforheroinaddiction
AT vijradhika buprenorphineoutpatientoutcomesprojectcansuboxonebeaviableoutpatientoptionforheroinaddiction
AT fergusonrobertp buprenorphineoutpatientoutcomesprojectcansuboxonebeaviableoutpatientoptionforheroinaddiction